Determining available strategies for prevention and therapy: Exploring COVID‑19 from the perspective of ACE2 (Review)
- Authors:
- Liyang Cai
- Xi Guo
- Yuchen Cao
- Peixi Ying
- Libing Hong
- Yuxi Zhang
- Guoguo Yi
- Min Fu
-
Affiliations: The Second Clinical School, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Medical College of Rehabilitation, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Ophthalmology, The Sixth Affiliated Hospital of Sun‑Yat‑Sen University, Guangzhou, Guangdong 510655, P.R. China, Department of Ophthalmology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510282, P.R. China - Published online on: February 8, 2021 https://doi.org/10.3892/ijmm.2021.4876
- Article Number: 43
-
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 395:565–574. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, et al: Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 8:475–481. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gralinski LE and Menachery VD: Return of the Coronavirus: 2019-nCoV. Viruses. 12:1352020. View Article : Google Scholar : | |
|
Wang G and Jin X: The progress of 2019 novel coronavirus event in China. J Med Virol. 92:468–472. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH and Osterhaus AD: A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA. 101:6212–6216. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY and Yan Y: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 7:112020. | |
|
Patel S, Rauf A, Khan H and Abu-Izneid T: Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 94:317–325. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kuba K, Imai Y, Ohto-Nakanishi T and Penninger JM: Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 128:119–128. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G and van Goor H: The emerging role of ACE2 in physiology and disease. J Pathol. 212:1–11. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kuhn JH, Li W, Choe H and Farzan M: Angiotensin-converting enzyme 2: A functional receptor for SARS coronavirus. Cell Mol Life Sci. 61:2738–2743. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W and Hao P: Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 63:457–460. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS and McLellan JS: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367:1260–1263. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G and Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 275:33238–33243. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 87:E1–E9. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Rice GI, Thomas DA, Grant PJ, Turner AJ and Hooper NM: Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 383:45–51. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G and Corvol P: Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 85:9386–9390. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Ehlers MR and Riordan JF: Angiotensin-converting enzyme: Zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry. 30:7118–7126. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Patel VB, Zhong JC, Grant MB and Oudit GY: Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 118:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH and Danser AH: Hypertension: Renin-angiotensin-aldosterone system alterations. Circ Res. 116:960–975. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Baig AM, Khaleeq A, Ali U and Syeda H: Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 11:995–998. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD and Neal B: The impact of 2019 novel coronavirus on heart injury: A systematic review and meta-analysis. Prog Cardiovasc Dis. 63:518–524. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G and van Goor H: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 203:631–637. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yan R, Zhang Y, Li Y, Xia L, Guo Y and Zhou Q: Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 367:1444–1448. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 11:875–879. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW and Xia Z: Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 35:1545–1549. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, et al: Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 251:228–248. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
da Silva JS, Gabriel-Costa D, Wang H, Ahmad S, Sun X, Varagic J, Sudo RT, Ferrario CM, Dell Italia LJ, Sudo GZ and Groban L: Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2. J Renin Angiotensin Aldosterone Syst. 18:14703203177222702017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579:270–273. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT and Veesler D: Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 181:281–292.e6. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ye R and Liu Z: ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol. 113:1043502020. View Article : Google Scholar | |
|
Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM and Butany J: SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 39:618–625. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, et al: Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5:819–824. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, et al: Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 26:369–375. 322–324. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Qi YF, Zhang J, Wang L, Shenoy V, Krause E, Oh SP, Pepine CJ, Katovich MJ and Raizada MK: Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia. J Mol Med (Berl). 94:37–49. 2016. View Article : Google Scholar | |
|
Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, Sigl V, Hanada T, Hanada R, Lipinski S, et al: ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 487:477–481. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrario CM and Mullick AE: Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 125:57–71. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, et al: Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 9:757–760. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, Bozkurt B, Braunwald E, Chopra VK, Cleland JG, et al: Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: An expert consensus position paper from the heart failure association (HFA) of the European society of cardiology (ESC). Eur Heart J. 41:2109–2117. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382:727–733. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim S, Rigatto K, Gazzana MB, Knorst MM, Richards EM, Pepine CJ and Raizada MK: Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 75:1063–1071. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Santisteban MM, Kim S, Pepine CJ and Raizada MK: Brain-gut-bone marrow axis: Implications for hypertension and related therapeutics. Circ Res. 118:1327–1336. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng PK, Wong DA, Tong LK, Ip SM, Lo AC, Lau CS, Yeung EY and Lim WW: Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 363:1699–1700. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, Yuen KY and Sung JJ: Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 125:1011–1017. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, Prasad R, Bhatwadekar A, White FA, Townsend SD, et al: Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. 67:1867–1879. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Vallianou NG, Stratigou T and Tsagarakis S: Microbiome and diabetes: Where are we now? Diabetes Res Clin Pract. 146:111–118. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P and Hansbro PM: Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 15:55–63. 2017. View Article : Google Scholar | |
|
Iyer SN, Lu D, Katovich MJ and Raizada MK: Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci USA. 93:9960–9965. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma RK, Yang T, Oliveira AC, Lobaton GO, Aquino V, Kim S, Richards EM, Pepine CJ, Sumners C and Raizada MK: Microglial cells impact gut microbiota and gut pathology in angiotensin II-induced hypertension. Circ Res. 124:727–736. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bron PA and Kleerebezem M: Lactic acid bacteria for delivery of endogenous or engineered therapeutic molecules. Front microbiol. 9:18212018. View Article : Google Scholar : PubMed/NCBI | |
|
Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F, et al: COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 116:1666–1687. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
South AM, Diz DI and Chappell MC: COVID-19, ACE2, and the cardiovascular consequences. Am J physiol Heart Circ physiol. 318:H1084–H1090. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Devaux CA, Rolain JM and Raoult D: ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 53:425–435. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426:450–454. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ge XY, Li JL, Yang XL, Chmura AA, Z hu G, E pstein JH, Mazet JK, Hu B, Zhang W, Peng C, et al: Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 503:535–538. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S and McCray PB Jr: ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 79:14614–14621. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Zhao S, Liu M, Zhao Z, Xu Y, Wang P, Lin M, Xu Y, Huang B, Zuo X, et al: ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. medRxiv. 2020–2022. 2020. | |
|
Cure E and Cumhur Cure M: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr. 14:349–350. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng Y, Zhang B, Zhang X and Yi C: Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection. Chin Med. 15:472020. View Article : Google Scholar : PubMed/NCBI | |
|
de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, et al: Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. Lancet. 395:1705–1714. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al: Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 126:1671–1681. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Daniel M, Bean ZK, Thomas S, Rebecca BA, Amos Folarin LR, Kevin OG and Rosita Zakeri AM: Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute hospital trust. NewsRX LLC; pp. 6122020 | |
|
Li J, Wang X, Chen J, Zhang H and Deng A: Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (Covid-19) infection in Wuhan, China. JAMA Cardiol. 5:825–830. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alexandre J, Cracowski JL, Richard V and Bouhanick B: Drugs, COVID-19' working group of the French Society Of Pharmacology, Therapeutics: Renin-angiotensin-aldosterone system and COVID-19 infection. Ann Endocrinol (Paris). 81:63–67. 2020. View Article : Google Scholar | |
|
Blaising J, Polyak SJ and Pécheur EI: Arbidol as a broad-spectrum antiviral: An update. Antiviral Res. 107:84–94. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J and Xue Y: Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 81:e21–e23. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Yang B, Li Q, Wen L and Zhang R: Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 71:769–777. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW and Polyak SJ: The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol. 90:3086–3092. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler Np, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ and White JM: Arbidol and other low-molecular-weight drugs that inhibit lassa and ebola viruses. J Virol. 93. pp. e02185–18. 2019, View Article : Google Scholar | |
|
Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X, Song W and Yi L: Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: A retrospective multicenter cohort study. Microbes Infect. 22:200–205. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG and Nichol ST: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2:692005. View Article : Google Scholar : PubMed/NCBI | |
|
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al: In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 71:732–739. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia: Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 43:185–188. 2020.In Chinese. | |
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269–271. 2020. View Article : Google Scholar : | |
|
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al: Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 56:1059492020. View Article : Google Scholar : PubMed/NCBI | |
|
Looareesuwan S, White NJ, Chanthavanich P, Edwards G, Nicholl DD, Bunch C and Warrell DA: Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol. 22:31–36. 1986. View Article : Google Scholar | |
|
Mackenzie AH: Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 75:40–45. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Penninger JM, Li Y, Zhong N and Slutsky AS: Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 46:586–590. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A and Einav S: A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 57:279–283. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J and Krähenbühl S: Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 5. 2:783–792. 2013. View Article : Google Scholar | |
|
Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, et al: A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 21:2342017. View Article : Google Scholar : PubMed/NCBI | |
|
Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del pozo C, Prosper F, et al: Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 181:905–913.e7. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ and Oudit GY: Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. J Mol Cell Cardiol. 66:167–176. 2014. View Article : Google Scholar | |
|
Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S and Shimamoto K: Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res. 29:865–874. 2006. View Article : Google Scholar | |
|
Igase M, Strawn WB, Gallagher PE, Geary RL and Ferrario CM: Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J physiol Heart Circ physiol. 289:H1013–H1019. 2005. View Article : Google Scholar | |
|
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI and Gallagher PE: Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 111:2605–2610. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M and Pearson JT: Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade. Biochem Pharmacol. 144:90–99. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sukumaran V, Veeraveedu PT, Lakshmanan AP, Gurusamy N, Yamaguchi K, Ma M, Suzuki K, Kodama M and Watanabe K: Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor. Free Radic Res. 46:850–860. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kocks MJ, Lely AT, Boomsma F, de Jong PE and Navis G: Sodium status and angiotensin-converting enzyme inhibition: Effects on plasma angiotensin-(1-7) in healthy man. J Hypertens. 23:597–602. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB and Ferrario CM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 43:970–976. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V and Srinivasan K: Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications. Biochem pharmacol. 93:343–351. 2015. View Article : Google Scholar | |
|
Shin YH, Min JJ, Lee JH, Kim EH, Kim GE, Kim MH, Lee JJ and Ahn HJ: The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels. 32:618–627. 2017. View Article : Google Scholar | |
|
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-poi H, et al: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 436:112–116. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kuba K, Imai Y, Rao S, Jiang C and Penninger JM: Lessons from SARS: Control of acute lung failure by the SARS receptor ACE2. J Mol Med (Berl). 84:814–820. 2006. View Article : Google Scholar | |
|
Huentelman MJ, Zubcevic J, Hernández prada JA, Xiao X, Dimitrov DS, Raizada MK and Ostrov DA: Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 44:903–906. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lo CS, Liu F, Shi Y, Maachi H, Chenier I, Godin N, Filep JG, Ingelfinger JR, Zhang SL and Chan JS: Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol. 302:F840–F852. 2012. View Article : Google Scholar : | |
|
Lusvarghi S and Bewley CA: Griffithsin: An antiviral lectin with outstanding therapeutic potential. Viruses. 8:2962016. View Article : Google Scholar : | |
|
O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL and McCray PB Jr: Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 84:2511–2521. 2010. View Article : Google Scholar : | |
|
Mori T, O'Keefe BR, Sowder RC II, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW Jr, McMahon JB and Boyd MR: Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 280:9345–9353. 2005. View Article : Google Scholar | |
|
Hu H, Li L, Kao RY, Kou B, Wang Z, Zhang L, Zhang H, Hao Z, Tsui WH, Ni A, et al: Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J Comb Chem. 7:648–656. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Han Dp, Penn-Nicholson A and Cho MW: Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 350:15–25. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, et al: Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 584:443–449. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, Tan TK, Rijal P, Dumoux M, Ward PN, et al: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 27:846–854. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pinheiro SV, Simões ESA, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, et al: Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 44:490–496. 2004. View Article : Google Scholar : PubMed/NCBI |
